Alnylam shares plunge after warning of possible demand decline from drug-price revisions
Alnylam Pharmaceuticals shares fell after the company warned that drug-price revisions could reduce demand.
Related stories
Silvercrest Asset Reports Third-Quarter Revenue of $32.7M
M impact | EQUITY | Oct 29, 2026, 08:29 PM UTC
Digital Realty Q3 Revenue Rises 21%, Lifts 2026 Outlook
Digital Realty Trust reported higher Q3 revenue and core FFO and lifted its 2026 outlook.
M impact | EQUITY | Oct 29, 2026, 08:18 PM UTC
eBay Reports Q3 Revenue of $3.21B, Net Income of $497M
Third-quarter 2026 revenue rose 13.7% year over year, while net income fell 20.9% and diluted EPS declined 17.9% to $1.10. eBay also completed its acquisition of Depop.
M impact | EQUITY | Oct 29, 2026, 08:15 PM UTC
Northern Trust Reports Third-Quarter Revenue of $2.29B, EPS of $3.40
Revenue rose 13.3% year over year to $2.29B. Net income applicable to common stock increased 42% to $626.7M, and diluted EPS rose 48.5% to $3.40.
M impact | EQUITY | Oct 29, 2026, 08:15 PM UTC
Silvercrest Asset reports third-quarter earnings
M impact | EQUITY | Oct 29, 2026, 08:15 PM UTC
Alignment Healthcare Q3 Revenue Beats; Cuts FY Adjusted Core Profit Outlook
M impact | EQUITY | Oct 29, 2026, 08:15 PM UTC